| Name | Title | Contact Details |
|---|
Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Our wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage trials in adult patients with classic congenital adrenal hyperplasia (CAH), with a planned Phase 2 trial in pediatric classic CAH. We aim to advance the treatment paradigm for classic CAH with a well-tolerated, non-steroidal approach designed to offer markedly improved disease control and reduced steroid burden for patients. Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including a rare form of polycystic ovary syndrome (PCOS).
Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.
Pearl Therapeutics is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
Aspen Medical Products is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.